<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30235730</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>04</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1536-5964</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>97</Volume>                    <Issue>38</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Medicine</Title>                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>            </Journal>            <ArticleTitle>Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy.</ArticleTitle>            <Pagination>                <MedlinePgn>e12447</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000012447</ELocationID>            <Abstract>                <AbstractText>The current study was to evaluate soluble ST-2 level and left ventricular ejection fraction (LVEF) in patients with breast cancer receiving doxorubicin or trastuzumab treatment for 6 months and determine whether soluble ST-2 level can be used to predictive left ventricular function impairment.Patients who were diagnosed as having breast cancer receiving doxorubicin or trastuzumab or combined therapy were enrolled. Demographic data, prior medical history and related medical therapy, and site and stage of breast cancer information were collected from electronic health record. Fasting blood was used to detect soluble ST-2 and brain natriuretic peptide (BNP) levels before and after 6 months doxorubicin or trastuzumab therapy. Echocardiography was performed before and after 6 months of doxorubicin or trastuzumab therapy.Participants were divided into 3 groups based on tertiary soluble ST-2 level. Compared with 1st tertiary group, patients in the 3rd tertiary group had higher proportion receiving combined therapy (14.3% vs 4.7%, P &lt; .05). Baseline soluble ST-2 level was similar across groups. After 6 months' therapy, soluble ST-2 level was significantly higher in the 3rd tertiary group. Pearson correlation analysis showed that soluble ST-2 level was positively correlated with left ventricular volume and E/e' ratio while negatively correlated with LVEF. Doxorubicin, trastuzumab, combined therapy, soluble ST-2 level, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker treatment were all independently associated with LVEF change.In breast cancer patients receiving doxorubicin or trastuzumab therapy, soluble ST-2 level can be used to predict cardiac function and structure changes.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Huang</LastName>                    <ForeName>Guoding</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Hainan Central Western Hospital, Danzhou, Hainan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhai</LastName>                    <ForeName>Jianfeng</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Hainan Central Western Hospital, Danzhou, Hainan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Huang</LastName>                    <ForeName>Xinting</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Hainan Central Western Hospital, Danzhou, Hainan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zheng</LastName>                    <ForeName>Dongdan</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Cardiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D003160">Comparative Study</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D064888">Observational Study</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Medicine (Baltimore)</MedlineTA>            <NlmUniqueID>2985248R</NlmUniqueID>            <ISSNLinking>0025-7974</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>114471-18-0</RegistryNumber>                <NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>80168379AG</RegistryNumber>                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>P188ANX8CK</RegistryNumber>                <NameOfSubstance UI="D000068878">Trastuzumab</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>AIM</CitationSubset>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2016 Feb;16(1):31-7</RefSource>                <PMID Version="1">26433876</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Psychol Rev. 2018 Jul;63:1-11</RefSource>                <PMID Version="1">29852324</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2002 Mar 1;20(5):1215-21</RefSource>                <PMID Version="1">11870163</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Circulation. 2015 Jan 6;131(1):54-61</RefSource>                <PMID Version="1">25403646</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Coll Cardiol. 2008 Oct 28;52(18):1458-65</RefSource>                <PMID Version="1">19017513</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Immunol Immunother. 2014 Jun;63(6):581-6</RefSource>                <PMID Version="1">24668364</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Exp Hypertens. 2018;40(6):554-559</RefSource>                <PMID Version="1">29400582</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Compr Canc Netw. 2013 Jul;11(7):753-60; quiz 761</RefSource>                <PMID Version="1">23847214</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Circ Cardiovasc Imaging. 2016 Jan;9(1):e003738</RefSource>                <PMID Version="1">26763280</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2013 Sep;24(9):2278-84</RefSource>                <PMID Version="1">23704196</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JACC Cardiovasc Imaging. 2013 Aug;6(8):877-85</RefSource>                <PMID Version="1">23643285</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Heart Fail. 2012 Mar;14(3):268-77</RefSource>                <PMID Version="1">22302661</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2014 Nov 20;32(33):3744-52</RefSource>                <PMID Version="1">25332249</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Immunity. 2005 Nov;23(5):479-90</RefSource>                <PMID Version="1">16286016</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Circulation. 2015 Jun 2;131(22):1981-8</RefSource>                <PMID Version="1">25948538</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2016 Apr;156(3):501-506</RefSource>                <PMID Version="1">27060913</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Can J Physiol Pharmacol. 2014 Jul;92(7):546-50</RefSource>                <PMID Version="1">24959994</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Circulation. 2017 Apr 11;135(15):1397-1412</RefSource>                <PMID Version="1">28104715</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2015 Oct 20;314(15):1599-614</RefSource>                <PMID Version="1">26501536</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2010 Jul 20;28(21):3416-21</RefSource>                <PMID Version="1">20530275</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Coll Cardiol. 2007 Aug 14;50(7):607-13</RefSource>                <PMID Version="1">17692745</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Clin Oncol. 2016 Mar;13(3):172-84</RefSource>                <PMID Version="1">26598943</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2013 Jan;14(1):72-80</RefSource>                <PMID Version="1">23246022</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA Intern Med. 2014 May;174(5):773-85</RefSource>                <PMID Version="1">24687000</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cardiol. 2018 Apr 15;257:125-130</RefSource>                <PMID Version="1">29506683</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Card Fail. 2015 Apr;21(4):355-61</RefSource>                <PMID Version="1">25451702</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Onco Targets Ther. 2018 Apr 19;11:2241-2250</RefSource>                <PMID Version="1">29719406</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D066126" MajorTopicYN="N">Cardiotoxicity</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006352" MajorTopicYN="N">Heart Ventricles</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011237" MajorTopicYN="Y">Predictive Value of Tests</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000068878" MajorTopicYN="N">Trastuzumab</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018487" MajorTopicYN="N">Ventricular Dysfunction, Left</DescriptorName>                <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30235730</ArticleId>            <ArticleId IdType="doi">10.1097/MD.0000000000012447</ArticleId>            <ArticleId IdType="pii">00005792-201809210-00078</ArticleId>            <ArticleId IdType="pmc">PMC6160077</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>